Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
To assess the effectiveness and safety of myoinositol for patients with PCOS.
In this meta-analysis, data from randomized controlled trials are obtained to assess the effects of myoinositol vs. placebo or western medicine in women with PCOS. The study’s registration number is CRD42017064563. The primary outcomes included total testosterone, estradiol (E2) and the homeostatic model assessment (HOMA) of insulin resistance.
Ten trials involving 573 patients were included. The meta-analysis results show that: compared with the control group, myoinositol may improve HOMA index (WMD −0.65; 95% CI −1.02, −0.28; P = 0. 0005) and increase the E2 level (WMD 16.16; 95% CI 2.01, 30.31; P = 0. 03); while there is no enough strong evidence that the myoinositol has an effect on the total testosterone level (WMD −16.11; 95% CI −46.08, 13.86; P = 0. 29).
Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS.
KeywordsMyoinositol Polycystic ovary syndrome Systematic review Meta-analysis
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
K.Y. and L.Z. contributed equally to this work.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Y. Meng, X. Chen, Z. Peng, X. Liu, Y. Sun, S. Dai, Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and meta-analysis. PLoS One 11, e0157389 (2016). https://doi.org/10.1371/journal.pone.0157389 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task force on the phenotype of the polycystic ovary syndrome of the androgen excess PCOS society 2009: The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRefPubMedGoogle Scholar
- 5.R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Androgen excess society 2006.:, Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006)CrossRefPubMedGoogle Scholar
- 12.J.E. Nestler, J.F. Strauss III, Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol. Metab. Clin. N. Am. 20, 807–823 (1991)Google Scholar
- 18.G. Donà, C. Sabbadin, C. Fiore, M. Bragadin, F.L. Giorgino, E. Ragazzi, G. Clari, L. Bordin, D. Armanini, Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol. 166, 703–710 (2012). https://doi.org/10.1530/EJE-11-0840 CrossRefPubMedGoogle Scholar
- 19.J.J. Deeks, J.P. Higgins, D.G. Altman, in Special Topics in Statistics, ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, Chapter 16 (The Cochrane Collaboration, UK, 2011)Google Scholar
- 20.J.J. Deeks, J.P. Higgins, D.G. Altman, in Assessing Risk of Bias in Included Studies, ed. by J.P. Higgins, S. Green Cochrane Handbook or Systematic Reviews of Interventions Version 5.1.0, Chapter 8 (The Cochrane Collaboration, UK, 2011)Google Scholar
- 21.J.J. Deeks, J.P. Higgins, D.G. Altman, in Analyzing Data and Undertaking Meta-analyses. ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, Chapter 9 (The Cochrane Collaboration, UK, 2011)Google Scholar
- 22.E. Benelli, S. Del Ghianda, C. Di Cosmo, M. Tonacchera, A combined therapy with Myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int. J. Endocrinol. 2016, 3204083 (2016). https://doi.org/10.1155/2016/3204083 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.P.G. Artini, O.M. Di Berardino, F. Papini, A.D. Genazzani, G. Simi, M. Ruggiero, V. Cela, Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol. 29, 375–379 (2013). https://doi.org/10.3109/09513590.2012.743020 CrossRefPubMedGoogle Scholar
- 26.A.D. Genazzani, C. Lanzoni, F. Ricchieri, V.M. Jasonni, Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol. Endocrinol. 24, 139–144 (2008). https://doi.org/10.1080/09513590801893232 CrossRefPubMedGoogle Scholar
- 30.Y. Loke, D. Price, A. Herxheimer, in Adverse Effects. ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions. Chapter 14. (Wiley, Chichester, UK, 2008)Google Scholar
- 37.J.P. Baillargeon, M.J. Iuorno, T. Apridonidze, J.E. Nestler, Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 8, 127–136 (2010). https://doi.org/10.1089/met.2009.0052 CrossRefPubMedGoogle Scholar